Vitreous Fatty Amides and Acyl Carnitines Are Altered in Intermediate Age-Related Macular Degeneration
暂无分享,去创建一个
H. Yoo | Ye An Kim | Young Lee | Seung-hyun Kwon | Jehyun Seo | Un Chul Park | C. Yoon | H. Yu
[1] Joan W. Miller,et al. Dyslipidemia in age-related macular degeneration , 2022, Eye.
[2] Dean P. Jones,et al. Plasma Metabolomics of Intermediate and Neovascular Age-Related Macular Degeneration Patients , 2021, Cells.
[3] Haixin Wang,et al. Untargeted metabolomics for uncovering plasma biological markers of wet age-related macular degeneration , 2021, Aging.
[4] Minoru Kanehisa,et al. KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..
[5] J. Seo,et al. Comparison of risk allele frequencies of single nucleotide polymorphisms associated with age-related macular degeneration in different ethnic groups , 2020, BMC Ophthalmology.
[6] C. Pan,et al. Metabolomics in Age-Related Macular Degeneration: A Systematic Review , 2020, Investigative ophthalmology & visual science.
[7] S. MacGregor,et al. The effects of eight serum lipid biomarkers on age-related macular degeneration risk: a Mendelian randomization study. , 2020, International journal of epidemiology.
[8] H. Hense,et al. Integrating metabolomics, genomics and disease pathways in age-related macular degeneration: The EYE-RISK Consortium. , 2020, Ophthalmology.
[9] Meiqin He,et al. Metabolomic Profiling of the Aqueous Humor in Patients with Wet Age-Related Macular Degeneration using UHPLC-MS/MS. , 2020, Journal of proteome research.
[10] Gui-Shuang Ying,et al. Age-Related Macular Degeneration Preferred Practice Pattern®. , 2019, Ophthalmology.
[11] Inês Laíns,et al. Human Plasma Metabolomics in Age-Related Macular Degeneration: Meta-Analysis of Two Cohorts , 2019, Metabolites.
[12] A. D. den Hollander,et al. Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway , 2019, PloS one.
[13] Jaeseung Kang,et al. Association of vitreous vitamin C depletion with diabetic macular ischemia in proliferative diabetic retinopathy , 2019, PloS one.
[14] A. D. den Hollander,et al. Metabolomics and Age-Related Macular Degeneration , 2018, Metabolites.
[15] Dean P. Jones,et al. The Carnitine Shuttle Pathway is Altered in Patients With Neovascular Age-Related Macular Degeneration , 2018, Investigative ophthalmology & visual science.
[16] P. Mitchell,et al. Age-related macular degeneration , 2018, The Lancet.
[17] Imre Lengyel,et al. A new perspective on lipid research in age-related macular degeneration , 2018, Progress in Retinal and Eye Research.
[18] Ivana K. Kim,et al. Human Plasma Metabolomics Study across All Stages of Age-Related Macular Degeneration Identifies Potential Lipid Biomarkers. , 2017, Ophthalmology.
[19] M. Maccarrone,et al. Neuroprotection by (Endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases , 2017, Current neuropharmacology.
[20] C. Klaver,et al. Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. , 2018, Survey of ophthalmology.
[21] Michael W. Country,et al. Retinal metabolism: A comparative look at energetics in the retina , 2017, Brain Research.
[22] Jost B. Jonas,et al. Updates on the Epidemiology of Age‐Related Macular Degeneration , 2017, Asia-Pacific journal of ophthalmology.
[23] W. Willett,et al. Dietary intake of α-linolenic acid and risk of age-related macular degeneration. , 2017, The American journal of clinical nutrition.
[24] Ivana K. Kim,et al. Human plasma metabolomics in age-related macular degeneration (AMD) using nuclear magnetic resonance spectroscopy , 2017, PloS one.
[25] E. Segal,et al. Involvement of a gut–retina axis in protection against dietary glycemia-induced age-related macular degeneration , 2017, Proceedings of the National Academy of Sciences.
[26] Timothy A. Blenkinsop,et al. Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. , 2017, Cell stem cell.
[27] Hyungwon Choi,et al. Customized Consensus Spectral Library Building for Untargeted Quantitative Metabolomics Analysis with Data Independent Acquisition Mass Spectrometry and MetaboDIA Workflow. , 2017, Analytical chemistry.
[28] Youngsoo Kim,et al. Carboxymethyl-lysine-modified plasma proteins in age-related macular degeneration , 2017, Biotechnology and Bioprocess Engineering.
[29] D. Kazan,et al. Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. , 2016 .
[30] A. Giersch,et al. The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications , 2016, Neural plasticity.
[31] Yue Han,et al. CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration , 2015, Scientific Reports.
[32] Zhifeng Wu,et al. Metabolomic Analysis of Human Vitreous in Rhegmatogenous Retinal Detachment Associated With Choroidal Detachment. , 2015, Investigative ophthalmology & visual science.
[33] K. Palczewski,et al. Serum levels of lipid metabolites in age‐related macular degeneration , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] G. Abecasis,et al. Age-related macular degeneration: genetics and biology coming together. , 2014, Annual review of genomics and human genetics.
[35] P. Jiang,et al. Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. , 2014, Molecular bioSystems.
[36] R. Klein,et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.
[37] Sina Farsiu,et al. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. , 2013, Ophthalmology.
[38] Usha Chakravarthy,et al. Clinical classification of age-related macular degeneration. , 2013, Ophthalmology.
[39] Joan W. Miller,et al. Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. , 2013, American journal of ophthalmology.
[40] B. McManus,et al. The Human Serum Metabolome , 2011, PloS one.
[41] Margaret A. Pericak-Vance,et al. Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration , 2010, Proceedings of the National Academy of Sciences.
[42] David S. Wishart,et al. SMPDB: The Small Molecule Pathway Database , 2009, Nucleic Acids Res..
[43] Philip Hunter,et al. Reading the metabolic fine print , 2009, EMBO reports.
[44] S. Black,et al. CARNITINE HOMEOSTASIS, MITOCHONDRIAL FUNCTION, AND CARDIOVASCULAR DISEASE. , 2009, Drug discovery today. Disease mechanisms.
[45] Usha Chakravarthy,et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.
[46] デュワン,アンドリュー,et al. Diagnosis and treatment of age-related macular degeneration , 2007 .
[47] I. Matias,et al. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.
[48] A. Ramé. [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.
[49] P. Bénit,et al. Succinate dehydrogenase deficiency in human , 2005, Cellular and Molecular Life Sciences CMLS.
[50] George A. Williams,et al. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. , 1999, Controlled clinical trials.
[51] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[52] Stem Cell Investigation , 2022 .
[53] S. Roth,et al. Clinical Interventions in Aging , 2022 .